Orthofix International N.V.NASDAQ:OFIX

Brad Mason - President & CEO

June 2017

Except for historical information contained herein, the statements made in this presentation

constitute ‘forward looking statements’ that involve certain risks and uncertainties. These forward

looking statements are based on our beliefs and expectations as of June 8, 2017, and we do not

undertake any obligation to revise or update such forward looking statements. Certain factors

may cause actual results to differ materially from those contained in the forward looking

statements, including those risks detailed from time to time in the Company’s reports on file at

the Securities and Exchange Commission.

Safe Harbor Statement and Use of Non-GAAP Measures

2

Orthofix may use certain non-GAAP financial measures in its presentations. Orthofix may use

non-GAAP financial measures as supplemental measures of performance and believes these

measures can provide useful information to investors in evaluating our operations, period over

period. However, non-GAAP financial measures have limitations as analytical tools, and should

not be considered in isolation or as a substitute for Orthofix’s financial results prepared in

accordance with GAAP. In addition, investors should note that any non-GAAP financial measures

Orthofix uses may not be the same non-GAAP financial measures, and may not be calculated in

the same manner, as that of other companies. Investors can find reconciliations of our non-GAAP

financial measures to the most directly comparable GAAP financial measures in our earnings

press releases.

Orthofix is a bone fusion company focused

on the design, manufacture and distribution

of a broad range of regenerative and repair

products worldwide.

3

By The Numbers

TTM Net Sales of $414 million

TTM Adjusted EBITDA of $80 million

TTM ROIC* of 10.4%

Global presence in over 70 countries

Sales breakdown: US - 80% OUS - 20%

Cash on March 31, 2017 of $42 million

No debt

$125 million credit facility available

4

* Using 38% tax rate

5

$0

$50

$100

$150

$200

$250

$300

$350

$400

2014 2015 2016 2017Guidance

CC Net Sales * Guidance Range

$0

$10

$20

$30

$40

$50

$60

$70

$80

$90

$100

2014 2015 2016 2017Guidance

CC Adj. EBITDA * Guidance Range

2.6% CAGR

14.1% CAGR

Constant Currency Net Sales and Adjusted EBITDA

* May 04, 2017 foreign exchange rates used for calculations

Net Sales Adjusted EBITDA

Bone Regeneration and Repair

BIOSTIM

EXTREMITY FIXATION

BIOLOGICS

SPINE FIXATION

REGENERATION

REPAIR

6

Our Strategic Business Units

43%

14%

25%

18%BioStim

Biologics

Extremity Fixation

Spine Fixation

Strategic Business Unit 2016 Net Sales ($M)

Total Net Sales $410

$73

$103

$58

$176

SBU 2016 NET SALES

7

Pulsed Electromagnetic Field technology (PEMF)

Strong clinical data and PMA Class III approval

Market leading spine and cervical products

CervicalStim™ device is only FDA-approved product for cervical spine

CAGR of 6% since 2013

Products primarily sold in the U.S.

BioStim – Bone Growth Stimulation

8

Market Size: $500M Market Share: 35% Market Position: #1Annual Market Growth Rate: 1% - 3%

* Internal Estimates

*

Bluetooth connectivity and mobile app (Stim

OnTrack™) designed to facilitate patient

compliance and improve spinal fusion outcomes

Enables physicians to receive real-time data on

patients’ adherence to their prescribed

treatment protocol

Many new patient comfort and convenience

features

FDA and CE Mark Approval for Next-Gen CervicalStim™

and SpinalStim™ Devices

9

BioStim Policy Recommendation from NASS

10

North American Spine Society’s (NASS)

Coverage Policy Recommendations

Released October 2016

First-of-its-kind coverage recommendations

for electrical bone growth stimulators

Specifically supports the use of PEMF

devices

Clinical evidence-based recommendations

Both cervical and lumbar regions

Biologics – Stem Cell Allograft

Human cellular and tissue-based business

Long-term partnership with Musculoskeletal Transplant Foundation (MTF)

Partners since 2008; current agreement runs to 2025

Trinity ELITE ® allograft tissue has surgeon preference advantages

Products primarily sold in the U.S.

11

Market Size: $300M Market Share: 30% Market Position: #2Annual Market Growth Rate: 3% - 5%

* Internal Estimates

*

Extremity Fixation

Leader in external fixation fracture repair, deformity correction and bone

reconstruction

Primarily external fixation devices, with complimentary internal fixation products

Ring fixation, pin-to-bar, plates, screws, nails

~35% of revenue from pediatric procedures

~75% of revenue from outside of the U.S.

12

Market Size: $800M Market Share: 13% Market Position: #5(External Fixation) Annual Market Growth Rate: 2% - 4%

*

* Internal Estimates

Spine Fixation

Implants for spine surgeries

Orthofix has a full line of outstanding spinal implants Cervical & Lumbar

Degenerative Disc Disease

MIS

Deformity Correction

Continuous stream of new products – 12 in 2016

~80% of revenue from the U.S.

13

Market Size: $9.0B Market Share: 1% Market Position: #9Annual Market Growth Rate: 1% - 3%

* Internal Estimates

*

Well Positioned For The Future

14

Achievement Highlights Since 2013

Orthofix of Today

People

PerformanceProducts

Processes

New Management Team Reconstituted Board of Directors Culture of Integrity & Performance Performance-Based Compensation

Investment in: Basic Science & Clinical Research Obtaining Tuck-In Technologies

Prolific new product Pipeline

Adj. EBITDA Expansion ~500 BPS Free Cash Flow Outlook TTM Double Digit ROIC Resolved Legacy SEC/DOJ Issues

Financial Controls Worldwide Oracle® & IT Upgrades Simplified Corporate & SBU Structures Order to Cash Process Improvements

15

Orthofix of Today Low to Mid Single-Digit Top Line Growth ~20% Adjusted EBITDA Margins Strong Free Cash Flow Double-Digit ROIC Opportunity to Leverage:

Leadership Team Infrastructure Financial Strength

The Next Chapter Creating additional shareholder value

Looking Ahead

16

Leverage our expanded distribution networks and

new product pipeline to accelerate sales growth in

each of our SBUs

Increase utilization of our BioStim products

• Clinical research to increase the number of

applications, find new indications and support

reimbursement

• Leverage NASS coverage recommendations to

expand patient access to this treatment

Continue to increase Adjusted EBITDA, free cash

flow and ROIC

2017 Organic Strategy

17

2017 Inorganic Strategy

18

Evaluate our current portfolio and structure to

maximize shareholder value

Acquire bolt-on products, technologies and distribution

that will drive sales in our existing businesses

Opportunistically pursue more substantial value

accretive acquisitions that leverage our market leading

positions

To us “value accretive” means:• Strong strategic fit to strengthen our business

• ROIC at least equal to WACC within planning period

• Accretive to EPS in relative near term

• Risk commensurate with strategic and financial

opportunity

Diversified business focused on bone fusion

Market leading position in bone growth stimulation

Global distribution footprint

Multiple avenues of growth opportunity

Investing in core technologies

Accelerating Free Cash Flow

Double-digit TTM ROIC

Strong balance sheet

Summary of Investment Highlights

19

Thank You

NASDAQ: OFIX www.orthofix.com

Investor Relations – Mark Quick

markquick@orthofix.com

© ORTHOFIX INC 2017

May 4, 2017